Expression and mechanism of regulation of PP2A/Pr65 in ameloblastoma.
OBJECTIVE
This study aimed to investigate the expression of PP2A/PR65 protein in ameloblastoma and the molecular mechanisms underlying the regulation of PP2A/PR65. The association between PP2A/PR65 and the clinicopathological characteristics of tumor specimens in ameloblastoma were to provide a theoretical basis for the diagnosis, therapy and prognosis of ameloblastoma.


METHODS
Streptavidin-peroxidase (S-P) immunohistochemical staining was used to detect PP2A/Pr65 expression changes in a total of 68 cases of ameloblastoma, six ameloblastic carcinomas, 21 squamous cell carcinomas and seven normal oral mucosas. Western blot was used to analyze PP2A/PR65 protein expression in 15 cases of ameloblastoma and three cases of normal oral mucosa.


RESULTS
Of the 68 cases analyzed, four cases were negative, 25 cases were weakly positive, 20 cases were moderately positive and 19 cases were strongly positive. In six cases of ameloblastic carcinoma, three cases were weak positive, one case was positive, two cases were strongly positive and none were negative. In 21 cases of squamous cell carcinomas, three cases were negative, 17 cases were weakly positive, one case was moderately positive and none were strongly positive. Western blot analysis showed that, PP2A/Pr65 protein expression was lower in ameloblastoma tissue compared with normal oral mucosa.


CONCLUSIONS
Reduced expression of PP2A/PR65 in ameloblastoma compared with normal oral mucosa indicates that PP2A/PR65 is involved in the occurrence and development of ameloblastoma.
Department of Pathology, Stomatological Hospital of China Medical University, Shenyang, Liaoning, China.
Xiuqiu
X
Gao
Foundation Institute, Liaoning Medical University, Jinzhou, Liaoning, China. Electronic address: guannabeibei@yahoo.com.cn.
Guannan
G
Wang
Department of Pathology, Stomatological Hospital of China Medical University, Shenyang, Liaoning, China.
Yun-Kai
YK
Zhang
Department of Pathology, Stomatological Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address: Zhongming_oral@yahoo.com.cn.
Ming
M
Zhong
D000293:Adolescent; D000328:Adult; D000368:Aged; D000564:Ameloblastoma / Q000235:genetics* / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D015153:Blotting, Western; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007573:Jaw Neoplasms / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000235:genetics* / Q000378:metabolism; D011379:Prognosis; D054648:Protein Phosphatase 2 / Q000096:biosynthesis / Q000235:genetics*; D012334:RNA, Neoplasm / Q000235:genetics*; D055815:Young Adult
D014408:Biomarkers, Tumor; D012334:RNA, Neoplasm; D054648:Protein Phosphatase 2
Ameloblastoma; Immunohistochemistry; PP2A; Western blot